MX2021010492A - Uso de la 2-fucosil-lactosa para aumentar la funcionalidad cerebral. - Google Patents
Uso de la 2-fucosil-lactosa para aumentar la funcionalidad cerebral.Info
- Publication number
- MX2021010492A MX2021010492A MX2021010492A MX2021010492A MX2021010492A MX 2021010492 A MX2021010492 A MX 2021010492A MX 2021010492 A MX2021010492 A MX 2021010492A MX 2021010492 A MX2021010492 A MX 2021010492A MX 2021010492 A MX2021010492 A MX 2021010492A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- fucosyl
- lactose
- increasing brain
- brain functionality
- Prior art date
Links
- HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 title abstract 2
- 210000004556 brain Anatomy 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 abstract 2
- 241001661355 Synapsis Species 0.000 abstract 1
- 230000000971 hippocampal effect Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000027928 long-term synaptic potentiation Effects 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pediatric Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Se describen métodos para mejorar el aprendizaje y/o la memoria, mejorar la adquisición de la memoria, la retención y recuperación de la memoria induciendo una mayor potenciación a largo plazo en la sinapsis neuronal hipocámpica en los individuos. Los métodos incluyen la administración de 2-fucosil-lactosa a un individuo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12382356.9A EP2708147B1 (en) | 2012-09-14 | 2012-09-14 | Methods for increasing brain functionality using 2-fucosyl-lactose |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021010492A true MX2021010492A (es) | 2021-10-01 |
Family
ID=46940437
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015003425A MX2015003425A (es) | 2012-09-14 | 2013-09-12 | Metodos para aumentar la funcionalidad cerebral al usar 2-fucosil-lactosa. |
MX2021010492A MX2021010492A (es) | 2012-09-14 | 2015-03-13 | Uso de la 2-fucosil-lactosa para aumentar la funcionalidad cerebral. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015003425A MX2015003425A (es) | 2012-09-14 | 2013-09-12 | Metodos para aumentar la funcionalidad cerebral al usar 2-fucosil-lactosa. |
Country Status (13)
Country | Link |
---|---|
US (1) | US10398715B2 (es) |
EP (2) | EP2708147B1 (es) |
CN (1) | CN104780785A (es) |
BR (1) | BR112015005794A2 (es) |
CA (1) | CA2884634A1 (es) |
DK (1) | DK2708147T3 (es) |
ES (1) | ES2795665T3 (es) |
IL (1) | IL237617A0 (es) |
MX (2) | MX2015003425A (es) |
MY (1) | MY180148A (es) |
PH (1) | PH12015500546A1 (es) |
SG (1) | SG11201501893XA (es) |
WO (1) | WO2014043368A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2572831T3 (es) | 2012-09-14 | 2016-06-02 | Abbott Laboratories | Composiciones nutricionales para su uso en métodos para modular los niveles de corticosterona en individuos con estrés psicológico |
EP2888950A1 (en) * | 2013-12-24 | 2015-07-01 | Abbott Laboratories | Methods for treating, preventing, or reducing neuroinflammation or cognitive impairment |
RU2706963C2 (ru) * | 2014-11-26 | 2019-11-21 | Абботт Лаборэтриз | Молочная смесь, содержащая олигосахариды грудного молока, полиненасыщенные жирные кислоты, нуклеотиды и лютеин |
MX2017006701A (es) * | 2014-11-26 | 2018-02-13 | Abbott Lab | Fórmula infantil con rrr-alfa-tocoferol,2'-fucosilactosa y un probiótico. |
US10835545B2 (en) | 2015-10-28 | 2020-11-17 | Glycom A/S | Synthetic composition and method for modulating brain function and behaviour |
EP3368047B1 (en) | 2015-10-28 | 2023-04-26 | Glycom A/S | Synthetic composition and method for modulating emotion and mood disorders |
KR101731263B1 (ko) * | 2016-04-25 | 2017-05-02 | 서울대학교 산학협력단 | 코리네박테리움 글루타미쿰을 이용한 2'-푸코실락토오스의 생산방법 |
WO2017215722A1 (en) * | 2016-06-15 | 2017-12-21 | Glycom A/S | Synthetic composition comprising hmo and method for modulating emotion and mood disorders |
RU2019105567A (ru) | 2016-07-28 | 2020-08-28 | Фонтерра Ко-Оперэйтив Груп Лимитед | Молочный продукт и способ |
CN110573030A (zh) * | 2017-05-24 | 2019-12-13 | 雀巢产品有限公司 | 用于增强注意力和/或降低冲动的营养组合物 |
WO2018215573A1 (en) * | 2017-05-24 | 2018-11-29 | Nestec S.A. | Composition comprising oligofructose (of) for use in the improvement of short term memory and other cognitive benefits |
MX2019011445A (es) | 2017-05-24 | 2019-11-18 | Nestle Sa | Composicion que comprende oligosacaridos de la leche humana (hmo) para usar en la mejora de la memoria a corto plazo y otros beneficios cognitivos. |
KR101953375B1 (ko) * | 2017-11-20 | 2019-02-28 | 고려대학교 산학협력단 | 다양하고 신규한 퓨코실 올리고당의 제조법 및 이의 용도 |
KR20190130720A (ko) * | 2018-05-15 | 2019-11-25 | (주)에이피테크놀로지 | 2'-푸코실락토오스를 포함하는 뇌졸중 예방용 조성물 |
WO2020178774A1 (en) * | 2019-03-05 | 2020-09-10 | Glycom A/S | Human milk oligosaccharides for use in enhancing executive function |
US20230414640A1 (en) | 2020-12-04 | 2023-12-28 | Societe Des Produits Nestle S.A. | Stable aqueous composition for preterm to promote early postnal growth |
CN114223723A (zh) * | 2021-12-13 | 2022-03-25 | 黑龙江飞鹤乳业有限公司 | 营养组合物、包含其的食品以及该营养组合物的用途 |
KR102570073B1 (ko) * | 2022-11-17 | 2023-08-24 | (주)에이피테크놀로지 | 2'-푸코실락토오스를 포함하는 치매 개선 또는 치료용조성물 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU694181B2 (en) * | 1994-03-09 | 1998-07-16 | Abbott Laboratories | Humanized milk |
KR970706271A (ko) | 1994-09-20 | 1997-11-03 | 스티븐슨 린다 에스. | 시냅스 전달 향상용 약제(drugs to improve synaptic transmission) |
RU2199317C2 (ru) | 1997-02-21 | 2003-02-27 | Абботт Лаборэтриз | Способ снижения заболеваемости некротическим энтероколитом у детей (варианты) |
US6365218B1 (en) | 2000-02-04 | 2002-04-02 | Abbott Laboratories | Pediatric formula and methods for providing nutrition and improving tolerance |
US6811801B2 (en) | 2001-12-12 | 2004-11-02 | Abbott Laboratories | Methods and compositions for brightening the color of thermally processed nutritionals |
US20110104716A1 (en) * | 2003-08-08 | 2011-05-05 | Hasan Mohejeri | Novel method for screening brain-active compounds |
WO2008011538A2 (en) | 2006-07-19 | 2008-01-24 | The Salk Institute For Biological Studies | Methods of using flavonoids to enhance memory |
MX2011004142A (es) | 2008-11-03 | 2011-05-25 | Nestec Sa | Una composicion nutricional que comprende probioticos y que mejora los patrones de sueño. |
CN102459295A (zh) * | 2009-04-07 | 2012-05-16 | 格礼卡姆股份公司 | 2’-o-岩藻糖基乳糖的合成 |
EP2451462B1 (en) | 2009-07-06 | 2017-09-06 | Children's Hospital Medical Center | Inhibiting inflammation with milk oligosaccharides |
CA2822660C (en) * | 2010-12-31 | 2021-09-07 | Abbott Laboratories | Synbiotic combination of probiotic and human milk oligosaccharides |
MX352040B (es) * | 2010-12-31 | 2017-11-07 | Abbott Lab | Formulaciones nutricionales que incluyen los oligosacaridos de leche humana y los acidos grasos poliinsaturados de cadena larga y usos de las mismas. |
WO2012092156A1 (en) * | 2010-12-31 | 2012-07-05 | Abbott Laboratories | Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides |
CN103379908B (zh) | 2010-12-31 | 2020-02-14 | 雅培制药有限公司 | 使用人乳寡糖、维生素c和抗炎剂减少氧化应激的发病率的方法 |
EP3338784B1 (en) * | 2010-12-31 | 2020-07-22 | Abbott Laboratories | Human milk oligosaccharides for modulating inflammation |
EP3335576A1 (en) * | 2010-12-31 | 2018-06-20 | Abbott Laboratories | Human milk oligosaccharides to promote growth of beneficial bacteria |
ES2601891T3 (es) | 2011-10-18 | 2017-02-16 | Nestec S.A. | Composición para su uso en crecimiento cerebral y/o desarrollo cognitivo y/o psicomotor |
ES2572831T3 (es) | 2012-09-14 | 2016-06-02 | Abbott Laboratories | Composiciones nutricionales para su uso en métodos para modular los niveles de corticosterona en individuos con estrés psicológico |
-
2012
- 2012-09-14 EP EP12382356.9A patent/EP2708147B1/en not_active Revoked
- 2012-09-14 ES ES12382356T patent/ES2795665T3/es active Active
- 2012-09-14 EP EP20161856.8A patent/EP3704957A1/en active Pending
- 2012-09-14 DK DK12382356.9T patent/DK2708147T3/da active
-
2013
- 2013-09-12 SG SG11201501893XA patent/SG11201501893XA/en unknown
- 2013-09-12 BR BR112015005794A patent/BR112015005794A2/pt not_active IP Right Cessation
- 2013-09-12 CA CA2884634A patent/CA2884634A1/en not_active Abandoned
- 2013-09-12 MY MYPI2015000615A patent/MY180148A/en unknown
- 2013-09-12 CN CN201380059274.1A patent/CN104780785A/zh active Pending
- 2013-09-12 US US14/428,247 patent/US10398715B2/en active Active
- 2013-09-12 WO PCT/US2013/059488 patent/WO2014043368A1/en active Application Filing
- 2013-09-12 MX MX2015003425A patent/MX2015003425A/es unknown
-
2015
- 2015-03-08 IL IL237617A patent/IL237617A0/en unknown
- 2015-03-13 PH PH12015500546A patent/PH12015500546A1/en unknown
- 2015-03-13 MX MX2021010492A patent/MX2021010492A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN104780785A (zh) | 2015-07-15 |
DK2708147T3 (da) | 2020-05-18 |
CA2884634A1 (en) | 2014-03-20 |
SG11201501893XA (en) | 2015-04-29 |
US10398715B2 (en) | 2019-09-03 |
EP2708147B1 (en) | 2020-03-11 |
MY180148A (en) | 2020-11-23 |
ES2795665T3 (es) | 2020-11-24 |
BR112015005794A2 (pt) | 2017-07-04 |
IL237617A0 (en) | 2015-04-30 |
EP2708147A1 (en) | 2014-03-19 |
WO2014043368A1 (en) | 2014-03-20 |
MX2015003425A (es) | 2015-06-22 |
US20150231159A1 (en) | 2015-08-20 |
PH12015500546A1 (en) | 2015-05-11 |
EP3704957A1 (en) | 2020-09-09 |
EP2708147A8 (en) | 2014-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015500546A1 (en) | Methods for increasing brain functionality using 2-fucosyl-lactose | |
HK1250620A1 (zh) | 假體瓣膜、框架和小葉及其方法 | |
HK1249002B (zh) | 改進的具有小葉支架的假體心臟瓣膜 | |
HK1215149A1 (zh) | 人工心瓣葉片中的平面區域 | |
EP3010448A4 (en) | Prosthetic heart valve with linking element and methods for implanting same | |
ZA201500887B (en) | Human anti-cd27 antibodies, methods and uses | |
MX2021001879A (es) | Combinaciones de dosificaciones para reducir las respuestas inmunes humorales no deseadas. | |
CA139448S (en) | Stimulation device | |
HK1170901A2 (en) | A smart adjustable human body model | |
IL242224B (en) | Methods for obtaining retinal progenitors, retinal pigmented epithelial cells and neural retinal cells | |
SG11201508115TA (en) | Rewriteable aberration-corrected gradient-index intraocular lenses | |
EP3230439A4 (en) | Human blood brain barrier model | |
EP2818135A4 (en) | PIN TO SUPPORT DENTAL PROSTHESIS AND METHOD FOR THE MANUFACTURE THEREOF | |
EP2901848A4 (en) | MASSIVE FIBER BODY AND ARTIFICIAL EARTH OF SOLID FIBER BODY | |
EP3191172A4 (en) | Nerve cuff electrode for neuromodulation in large human nerve trunks | |
CA152179S (en) | Analytical apparatus for drug testing | |
HUE050729T2 (hu) | Fogászati implantátum, felépítmény, implantátum rendszer és implantációs készlet | |
EP3005981A4 (en) | IMPLANTABLE LENS FOR MYOPIA AND METHOD FOR PREPARING SAID LENS | |
IL245086A0 (en) | Retaining matrix system and dental implant | |
WO2014179771A8 (en) | Dosing combinations for reducing undesired humoral immune responses | |
EP2865666A4 (en) | HEXAHYDROPENTALENE DERIVATIVES, METHOD OF MANUFACTURE AND USE IN MEDICINE | |
WO2014135878A3 (en) | Methods for treating cells with immunosuppressants to enhance their immunosuppressive potency | |
EP2952160A4 (en) | ORGANIC LIGHT TREATMENT SYSTEM, AND ENDOPROTHESIS | |
DK3011760T3 (da) | Mellemøretransducer med biokompatibel implanterbar klæbepude | |
AU2013904589A0 (en) | System and method for the capture and representation of the logic, structure, pattern and emotion of daily interactions as a habit, sequence or a regular course of procedure in the daily routine of people with disabilities |